Eli Lilly

AskBio Names Mansuo Shannon Chief Scientific Officer

Retrieved on: 
Tuesday, April 9, 2024
Eli Lilly, Alzheimer's disease, Gene editing, Princeton University, MIT, Research, Bayer, Chugai Pharmaceutical Co., Doctor of Philosophy, Samulski, Therapy, Eli Lilly and Company, CSO, Molecular biology, Management

Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Key Points: 
  • Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
    Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
    Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that on April 8, 2024, Mansuo Shannon, PhD, was named the company’s next Chief Scientific Officer (CSO).
  • Shannon joins AskBio from Prevail Therapeutics, where she also served as CSO.
  • Reporting to Gustavo Pesquin, Chief Executive Officer (CEO), Shannon will be a member of AskBio’s Executive Leadership Team and head its R&D organization.
  • As part of her role as CSO at AskBio, Shannon will develop and implement the company’s future R&D strategy.

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Retrieved on: 
Wednesday, March 27, 2024
Eli Lilly, Disease, Half-life, Partnership, Patient, Sale, Acquisition, Inflammation, Therapy, OrbiMed, Hidradenitis suppurativa, Probability, Autoimmune disease

Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027

Key Points: 
  • Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027
    Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.
  • The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million.
  • After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million.
  • The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions.

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Retrieved on: 
Wednesday, March 27, 2024
Transforming growth factor beta, Eli Lilly, Atrophy, DVM, Obesity, Drug discovery, Exercise, Partnership, Patient, SAN, EDT, Learning, Entrepreneurship, IND, Antibody, Drug development, PIPE, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.

Key Points: 
  • Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors.
  • The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
  • The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise.
  • iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

AMERICAN SKIN ASSOCIATION SPRING GALA CELEBRATES OUTSTANDING HONOREES

Retrieved on: 
Friday, April 5, 2024
Eli Lilly, Organization, Master of ceremonies, Psoriasis, Vitiligo, Atopic dermatitis, Skin cancer, NBC, Patient, Research, Pioneer, Hope, Doctor of Philosophy, MD, Student, Inauguration, SPOTS, ASA, Skin, Melanoma, Eli Lilly and Company, Plaza Hotel, Physician, Pharmaceutical industry

NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala. They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health. The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.

Key Points: 
  • Gala honors Pioneer in Dermatology, Emma Guttman-Yassky, MD, PhD and Global Pharmaceutical Leader Eli Lilly and Company
    NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala.
  • They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health.
  • The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.
  • Recipients, who work on breakthrough efforts to prevent, detect, and treat skin cancer and other skin diseases, have gone on to become top researchers in dermatology.

ProQR Announces Year End 2023 Operating and Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Trident, Eli Lilly, Exercise, ProQR, Patient, IP, Therapy, Lilly, RNA editing, Cholestasis, Rett syndrome, Research, Cardiovascular disease, Partnership, Pseudouridine, NTCP, RNA, Functional, Uridine, MECP2, Oligonucleotide, ACTB, LPL, Annual report, Conference, Patent, Biomarker, Mouse, RSRT, Eli Lilly and Company, Liver, ANGPTL3

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
  • At December 31, 2023, ProQR held cash and cash equivalents of €118.9 million, compared to €94.8 million at December 31, 2022.
  • The Company experienced a net positive cash flow from operating activities in 2023 primarily due to the receipt of the Lilly up-front payment of $60 million in February 2023.
  • For further financial information for the period ended December 31, 2023, please refer to our 2023 Annual Report on Form 20-F and our Statutory Annual Report which will be available on our website, www.

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Retrieved on: 
Tuesday, April 2, 2024
Medical Devices, FDA, Health, Health Technology, General Health, Pharmaceutical, Eli Lilly, Combination, DCT, Microsoft Research, Artificiality, Trust (social science), GSK, Novartis, Patient, Food and Drug Administration, Artificial intelligence, USS Midway, AI, EMA, Merck & Co., Medicine, European Medicines Agency, Johnson & Johnson, Ecosystem, Drug development, Pharmacovigilance, Food, DIA, Student, Diamond, DEI, Medical device

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.

Key Points: 
  • The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.
  • Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world's preeminent neutral life sciences forum — and the only thing missing is you.
  • "This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we're celebrating by continuing to forge a bold future marked by innovation and impact," said Marwan Fathallah, DIA's President and Global Chief Executive.
  • — An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today's regulatory, scientific, and communication challenges.

2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

Retrieved on: 
Friday, March 22, 2024
Professional Services, Business, Fintech, Training, Start-Up, Technology, Small Business, University, Artificial Intelligence, Education, Biotechnology, Finance, Health, MCAP, Beam Therapeutics, Eli Lilly, Membrane, Innovation, Growth, Insight Partners, Beam, The Ritz-Carlton Hotel Company, GOLD, Blumberg Capital, LYFT, AI, LPCE, Creativity, Senior advisor, Boston College High School, AUM, Former, Summit, Third Rock Ventures, VCG, Sirtris Pharmaceuticals

The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston.

Key Points: 
  • The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston.
  • The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors.
  • The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI.
  • “For this year’s Entrepreneurship Summit, we are excited to build off of the momentum of last year’s leadership and take it to new heights.

Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Health, Other Science, Finance, Research, Science, Biotechnology, RAPS, Eli Lilly, AstraZeneca, Ferris State University, Patient, Esperion Therapeutics, Sale, IPO, Pleasure, Esperies, Insys Therapeutics, Therapy, Investment, Multimedia, Pharmaceutical industry

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240312683597/en/
    Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors.
  • Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies.
  • We are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.